Filtered By:
Cancer: Small Cell Lung Cancer

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 24 results found since Jan 2013.

Silencing SATB1 with siRNA inhibits the proliferation and invasion of small cell lung cancer cells
Background: Small cell lung cancer (SCLC) is a special kind of lung cancers, lymph or blood metastasis of SCLC usually occurs in early stage. Studies in breast and colon cancer showed over expression of SATB1 could promote tumor cell growth and inhibit apoptosis. Therefore, we studied the expression of SATB1 in SCLC. Methods: The level of SATB1 was analyzed in SCLC tissues, metastatic lymphoid nodes and adjacent normal lung tissues by immunohistochemistry. Meanwhile, small interfering SATB1-targeting RNA was constructed and transfected into human SCLC cell line NCI-H446 to evaluate the effects of SATB1-siRNA on cell prolif...
Source: Cancer Cell International - February 5, 2013 Category: Cancer & Oncology Authors: Bo HuangHongli ZhouXiaodong WangZhiliang Liu Source Type: research

Abstract 4954: Serine/arginine splicing factor 1 (SRSF1) mediates DNA repair and chemo-sensitivity and drives growth in small cell lung cancer
Small cell lung cancer (SCLC) is the most aggressive subtype of lung cancer. Despite a high response rate to chemotherapy, more than 95% of patients eventually die from SCLC. We have identified that Serine/Arginine Splicing Factor 1 (SRSF1) DNA copy number gain and mRNA over-expression in tumor is strongly associated with poor survival based on whole exome sequencing (WES) and transcriptomic sequencing of primary tumors from 99 Chinese SCLC patients. Here, SRSF1 is evaluated as a tumor driver in SCLC. Treatment of SCLC cell lines in vitro with a low dose of cisplatin or topotecan (two of the most common standard of care in...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Conley, S. J., Yao, X., Huang, J., Higgs, B., Hu, Z., Xiao, Z., Zhong, H., Liu, Z., Brohawn, P., Ge, X., Czapiga, M., Oganesyan, V., Fu, H., Tice, D., Herbst, R., Su, X., Gu, Y., Gu, J., Han, B., Richman, L., Jallal, B., Jiang, L., Shen, H., Yao, Y. Tags: Molecular and Cellular Biology Source Type: research

Abstract 1735: Identification of novel synthetic lethal interactions in small cell lung cancer with the proteasome inhibitor carfilzomib
Proteasome inhibition (PI) has emerged as a valuable cancer treatment in hematological malignancies by causing a disruption of protein homeostasis. While proteasome inhibitors have been historically unsuccessful in the clinic for solid tumors, all cancer cell lines succumb to proteasome inhibition in vitro. Solid tumor cell lines have a higher threshold for disruption of protein homeostasis; as they require continuous exposure to achieve cytotoxicity similar to pulsatile exposure of PI in heme cell lines. The in-vivo half-life of proteasome inhibitors is short (∼1hr) making it challenging to mimic in vitro continuous tre...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Masto, V. B., Lerner, A. G., Arastu-Kapur, S. Tags: Experimental and Molecular Therapeutics Source Type: research

TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma
In conclusion, BDNF/TrkB signal is involved in malignant progression of invasiveness and tumorigenicity for LCNEC, and may be a potential target for LCNEC without standard therapy.
Source: Lung Cancer - January 10, 2013 Category: Cancer & Oncology Authors: Seiichi Odate, Katsuya Nakamura, Hideya Onishi, Masayuki Kojima, Akihiko Uchiyama, Kenji Nakano, Masato Kato, Masao Tanaka, Mitsuo Katano Tags: Carcinogenesis and molecular biology Source Type: research

Differential regulation of MMPs by E2F1, Sp1 and NF-kappa B controls the small cell lung cancer invasive phenotype
Conclusions: E2F1 acts as a transcriptional activator for MMPs and directly enhances MMP transcription by binding to E2F1 binding sequences in the promoter, or indirectly activates MMPs through enhanced Sp1 and NF-kappa B as a consequence of E2F1 activation in SCLC.
Source: BMC Cancer - April 22, 2014 Category: Cancer & Oncology Authors: Zunling LiYanxia GuoHanming JiangTingguo ZhangChangzhu JinCharles YoungHuiqing Yuan Source Type: research

Abstract 4: ABT-263 is effective in a subset of non-small cell lung cancer cell lines
Conclusion:We found that Calu3 and BID007 were sensitive to ABT-263. In the sensitive NSCLC cell lines, ABT-263 induces apoptosis irrespective of Mcl-1 expression levels.Citation Format: Aoi Kuroda, Keiko Ohgino, Hiroyuki Yasuda, Junko Hamamoto, Daisuke Arai, Kota Ishioka, Tetsuo Tani, Shigenari Nukaga, Ichiro Kawada, Katsuhiko Naoki, Kenzo Soejima, Tomoko Betsuyaku. ABT-263 is effective in a subset of non-small cell lung cancer cell lines. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Kuroda, A., Ohgino, K., Yasuda, H., Hamamoto, J., Arai, D., Ishioka, K., Tani, T., Nukaga, S., Kawada, I., Naoki, K., Soejima, K., Betsuyaku, T. Tags: Molecular and Cellular Biology Source Type: research

Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
Authors: Inoue H, Kato T, Olugbile S, Tamura K, Chung S, Miyamoto T, Matsuo Y, Salgia R, Nakamura Y, Park JH Abstract Maternal embryonic leucine zipper kinase (MELK), that plays a critical role in maintenance of cancer stem cells (CSCs), is predominantly expressed in various types of human cancer including small cell lung cancer (SCLC). SCLC usually acquires resistance to anti-cancer drugs and portends dismal prognosis. We have delineated roles of MELK in development/progression of SCLC and examined anti-tumor efficacy of OTS167, a highly potent MELK inhibitor, against SCLC. MELK expression was highly upregulated i...
Source: Oncotarget - February 13, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Role of homeobox gene A5 in multidrug resistance of human small cell lung cancer cells.
CONCLUSION: HOXA5 may play an important role in multidrug resistance of SCLC and can be a potential therapeutic target in clinical treatment of SCLC. PMID: 24273274 [PubMed - as supplied by publisher]
Source: Journal of Southern Medical University - November 20, 2013 Category: Universities & Medical Training Authors: Xiao FM, Chen ZZ, Zeng XP, Bai YF, Guo LL, Li YF Tags: Nan Fang Yi Ke Da Xue Xue Bao Source Type: research

Role of Pax8 in the regulation of MET and RON receptor Tyrosine Kinases in non-small cell lung cancer
Conclusion: PAX8 provides signals for growth and motility of NSCLC cells and is necessary for MET and RON expression. Further investigations are necessary to investigate the therapeutic potential of PA8 in NSCLC.
Source: BMC Cancer - March 14, 2014 Category: Cancer & Oncology Authors: Rajani KantetiEssam El-HashaniImmanuel DhanasinghMaria TretiakovaAliya HusainSherven SharmaJay SharmaEverett VokesRavi Salgia Source Type: research

Significance of c‐MET Overexpression in Cytotoxic Anticancer Drug Resistant Small Cell Lung Cancer Cells
In conclusion, increased c‐Met expression through an increase in the number of c‐MET gene loci is one of mechanisms of acquired resistance to the cytotoxic anticancer drugs. Our results add a new strategy that c‐MET is a target for overcoming the resistance to cytotoxic agents in SCLC. This article is protected by copyright. All rights reserved.
Source: Cancer Science - May 1, 2014 Category: Cancer & Oncology Authors: Hiroaki Ozasa, Tetsuya Oguri, Ken Maeno, Osamu Takakuwa, Eiji Kun, Yoshitaka Yagi, Takehiro Uemura, Daishi Kasai, Mikinori Miyazaki, Akio Niimi Tags: Original Article Source Type: research

Role of SPHK1 Regulates Multi-drug Resistance of Small Cell Lung Cancer
and Its Clinical Significance
Background and objective Lung cancer is the leading cause of cancer-related deaths worldwide. Approximately 15% of all histological types consist of small cell lung cancer (SCLC). Chemotherapy is one of the major treatment method. Though the current first-line standard chemotherapy regimen for SCLC is active in most SCLC cases, however the disease recurs shortly after the first successful treatment with multi-drug resistance (MDR) phenotype. Our previously study showed that SPHK1 was associated with MDR in SCLC. The aim of this study is to investigate the role of sphingosine kinase 1 (SPHK1) showed in small cell lung multi...
Source: Chinese Journal of Lung Cancer - November 18, 2014 Category: Cancer & Oncology Source Type: research

MTA1 downregulation inhibits malignant potential in a small cell lung cancer cell line.
Authors: Xue H, Wang H, Liu J, Liu H, Li C, Han L, Lin C, Zhan Q, Zhao Z, Qian H Abstract As a component of the nuclear remodeling and deacetylation complex (NuRD complex), metastasis-associated gene 1 (MTA1) has been reported to play a key role in cancer malignancy. However, whether MTA1 functions in small cell lung cancer (SCLC) malignant behavior and whether it is feasible to be used as a therapeutic target have not been evaluated. The present study aimed to investigate the effects of MTA1 downregulation on SCLC malignancy. First we demonstrated the overexpression of MTA1 in SCLC specimens. After knocking down ...
Source: Oncology Reports - December 18, 2014 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Abstract 3841: Effects of KEAP1 genetic and epigenetic silencing in SCLC cell lines
Conclusions. Our data provide new insights into the potential downstream effects of genetic and epigenetic Keap1/Nrf2 molecular deregulation in SCLCs, suggesting that the impairment of Keap1 activity actually induces the expression of cytoprotective enzymes also in small cell lung cancer cells. Validations on tissues from SCLC affected patients combined with in vitro pharmacological studies are demanded to establish new combined therapeutic strategies in targeted cancer treat-ments of this aggressive lung tumour histotype.Citation Format: Domenico Trombetta, Annamaria la Torre, Angelo Sparaneo, Teresa Balsamo, Massimiliano...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Trombetta, D., la Torre, A., Sparaneo, A., Balsamo, T., Copetti, M., Sanchez-Cespedes, M., Maiello, E., Graziano, P., Fazio, V. M., Muscarella, L. A. Tags: Molecular and Cellular Biology Source Type: research

Insulinoma-Associated Protein 1 Is a Crucial Regulator of Neuroendocrine Differentiation in Lung Cancer.
Abstract Insulinoma-associated protein 1 (INSM1) is expressed exclusively in embryonic developing neuroendocrine (NE) tissues. INSM1 gene expression is specific for small-cell lung cancer (SCLC), along with achaete-scute homolog-like 1 (ASCL1) and several NE molecules, such as chromogranin A, synaptophysin, and neural cell adhesion molecule 1. However, the underlying biological role of INSM1 in lung cancer remains largely unknown. We first showed that surgically resected SCLC samples specifically expressed INSM1. Forced expression of the INSM1 gene in adenocarcinoma cell lines (H358 and H1975) induced the expressi...
Source: The American Journal of Pathology - October 16, 2015 Category: Pathology Authors: Fujino K, Motooka Y, Hassan WA, Ali Abdalla MO, Sato Y, Kudoh S, Hasegawa K, Niimori-Kita K, Kobayashi H, Kubota I, Wakimoto J, Suzuki M, Ito T Tags: Am J Pathol Source Type: research

Expression of ADAM12 is regulated by E2F1 in small cell lung cancer.
Authors: Li Z, Wang Y, Kong L, Yue Z, Ma Y, Chen X Abstract Our previous study reported that ADAM12 was highly expressed in small cell lung cancer (SCLC) and could be an effective marker for diagnosis and prognosis. Yet, the reason for the high expression of ADAM12 in SCLC requires further elucidation. Transcription factor E2F1 has been receiving increasing attention due to the complexity and diversity of its function in cancer. In the present study, the expression of ADAM12 was significantly decreased following silencing of E2F1 expression by siRNA, thus indicating that E2F1 may regulate the expression of ADAM12 a...
Source: Oncology Reports - October 30, 2015 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research